跳至主要内容
临床试验/NCT03748719
NCT03748719撤回不适用

A Single Arm Phase II Trial of Preoperative Stereotactic Body Radiation Therapy (SBRT) for T3a or Gleason Grade Group 4 Prostate Cancer

H. Lee Moffitt Cancer Center and Research Institute0 个研究点开始时间: 2018年11月19日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
主要终点
Measure of PSA (Prostate Specific Antigen)

研究概览

简要总结

This study involves Stereotactic Body Radiation Therapy (SBRT) followed by prostatectomy (removal of the prostate). SBRT is a relatively new radiation technique in which a few doses of radiation are delivered to small, well-defined tumors. It has been used effectively in other cancers like lung and liver. The radiation will be given for only 5 days.

The purpose of this study is to compare the effects, good and/or bad, of different doses of SBRT given before prostatectomy.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Measure of PSA (Prostate Specific Antigen)

时间窗: Up to 12 months

Measure of PSA through treatment. PSA is expected to be undetectable (\<0.2 mg/ml) after prostatectomy and radiation therapy.

Number of symptomatic adverse anastomotic events

时间窗: Up to 12 months

Number of symptomatic anastomotic events related to pre-operative SBRT.

次要结局

  • Mean Catheterization Time(Up to 4 weeks post surgery)
  • Mean Hospital Stay(Up to 2 week post surgery)
  • Quality of Life assessment(Baseline, at 2 weeks, 4 weeks, 2 months and every 3 months up to 12 months post surgery)

研究者

申办方类型
Other
责任方
Sponsor

相似试验